Physician profile
William A Hill
NPI 1780648394
$6,629.60
in general payments reported to CMS, 2019-2025
32 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,985 · 2020: $1,150 · 2021: $1,174 · 2022: $999 · 2023: $526 · 2024: $539 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,121.03 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $863.11 | 2019-2024 | Opsumit, Uptravi |
| Amgen INC. | $643.76 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $588.43 | 2019-2022 | |
| Abbott Laboratories | $328.74 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $243.08 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $192.54 | 2019-2022 | |
| Medtronic Vascular, INC. | $171.18 | 2019 | |
| Novo Nordisk INC | $168.80 | 2025 | Wegovy |
| Amarin Pharma, INC. | $143.19 | 2019-2021 | |
| Gilead Sciences, INC. | $138.14 | 2019 | |
| Philips North America LLC | $122.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.65 | 2021-2023 | Jardiance |
| Medtronic, INC. | $94.68 | 2021-2025 | Pulseselect |
| Merck Sharp & Dohme LLC | $83.34 | 2022-2024 | Verquvo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $82.33 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.31 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $68.34 | 2019-2021 | |
| Kinamed, INC. | $58.43 | 2024 | |
| Pfizer INC. | $51.77 | 2019-2021 | |
| United Therapeutics Corporation | $40.18 | 2019-2020 | |
| Cardiovascular Systems INC. | $33.21 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.62 | 2021 | |
| Cvrx, INC. | $25.35 | 2023 | Barostim Neo System |
| Portola Pharmaceuticals, LLC | $25.25 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $24.83 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $24.06 | 2023 | Zio Xt Patch |
| Kowa Pharmaceuticals America, INC. | $19.03 | 2019 | |
| Chiesi USA, INC. | $15.62 | 2019 | |
| Bracco Diagnostics INC. | $13.66 | 2022 | |
| Boston Scientific Corporation | $12.84 | 2019 | |
| Shockwave Medical, INC | $12.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.